​

Bioventus (BVS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BVS Stock Forecast

Bioventus (BVS) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a 14.39% increase from the last price of $10.49.

$3 $5 $7 $9 $11 $13 $14 High: $12 Avg: $12 Low: $12 Last Closed Price: $10.49

BVS Stock Rating

Bioventus stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

BVS Forecast vs Benchmarks

TypeNameUpside
StockBioventus14.39%
SectorHealthcare Stocks 25.20%
IndustryMedical Device Stocks6.39%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$10.25
Last Closing Price$10.49$10.49$10.49
Upside/Downside---2.29%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25-21--3
Dec, 24-21-14
Nov, 24-2-114
Oct, 24-2-114
Sep, 24-2-114
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 01, 2024Caitlin CroninCanaccord Genuity$12.00$11.791.78%14.39%
Aug 07, 2024Chase KnickerbockerCraig-Hallum$12.00$8.2545.45%14.39%
May 07, 2024William PlovanicCanaccord Genuity$8.00$5.1256.25%-23.74%
Mar 13, 2024Alex NowakCraig-Hallum$9.00$5.2970.13%-14.20%
Nov 30, 2022Goldman Sachs$2.50$1.9130.89%-76.17%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024RBC CapitalOutperformupgrade
Oct 01, 2024Canaccord GenuityBuyBuyhold
Sep 27, 2024Craig-HallumBuyBuyhold
Aug 07, 2024Craig-HallumBuyBuyhold
May 07, 2024Canaccord GenuityBuyBuyhold
Dec 07, 2023Canaccord GenuityBuyupgrade
Nov 30, 2022Goldman SachsNeutralNeutralhold
Nov 22, 2022Craig-HallumHolddowngrade

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$0.44$0.16$-3.48$-2.49---
Avg Forecast$0.86$0.90$0.26$-0.30$0.40$0.56$0.78
High Forecast$0.86$0.90$0.25$-0.31$0.39$0.55$0.43
Low Forecast$0.86$0.90$0.26$-0.29$0.42$0.59$1.13
Surprise %-48.84%-82.22%-1438.46%730.00%---

Revenue Forecast

$300M $370M $440M $510M $580M $650M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$321.16M$430.90M$512.12M$512.35M---
Avg Forecast$320.87M$430.39M$521.72M$500.90M$564.94M$570.79M$607.84M
High Forecast$319.56M$428.64M$510.79M$492.67M$555.66M$561.41M$607.76M
Low Forecast$321.72M$431.54M$528.07M$517.14M$583.25M$589.29M$607.92M
Surprise %0.09%0.12%-1.84%2.29%---

Net Income Forecast

$-250M $-180M $-110M $-40M $30M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$16.41M$9.59M$-213.39M$-156.23M---
Avg Forecast$53.88M$56.44M$16.13M$-19.03M$25.45M$35.76M$48.87M
High Forecast$53.59M$56.14M$15.69M$-19.62M$24.65M$34.63M$26.93M
Low Forecast$54.06M$56.64M$16.39M$-18.43M$26.25M$36.88M$70.80M
Surprise %-69.54%-83.02%-1422.80%721.18%---

BVS Forecast FAQ

Is Bioventus stock a buy?

Bioventus stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bioventus is a favorable investment for most analysts.

What is Bioventus's price target?

Bioventus's price target, set by 4 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential 14.39% change from the previous close price of $10.49.

How does Bioventus stock forecast compare to the average forecast of its sector, industry, and investment themes?

Bioventus stock forecast shows a 14.39% upside, underperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the medical device stocks industry (6.39%).

What is the breakdown of analyst ratings for Bioventus over the past three months?

  • January 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 0% Strong Buy, 50.00% Buy, 25.00% Hold, 0% Sell, 25.00% Strong Sell.
  • November 2024: 0% Strong Buy, 50.00% Buy, 0% Hold, 25.00% Sell, 25.00% Strong Sell.

What is Bioventus’s EPS forecast?

Bioventus's average annual EPS forecast for its fiscal year ending in December is 0.4 for 2024, a -116.06% decrease from the reported $-2.49 in 2023. The prediction for 2025 is $0.56, and $0.78 for 2026.

What is Bioventus’s revenue forecast?

Bioventus's average annual revenue forecast for its fiscal year ending in December is $564.94M for 2024, a 10.27% increase from the reported $512.34M in 2023. The forecast for 2025 is $570.79M, and $607.84M for 2026.

What is Bioventus’s net income forecast?

For its fiscal year ending in December, Bioventus's average annual net income forecast is $25.45M for 2024, reflecting a -116.29% decrease from the reported $-156M in 2023. The projection for 2025 is $35.76M, and $48.87M for 2026.